Xenetic Biosciences (XBIO) 10-K2022 FY Annual report

Filed: 22 Mar 23, 4:30pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abraxane, addendum, adenocarcinoma, adept, adjunct, adjunctive, aggravated, al, allotted, amelioration, armored, armoring, autoimmune, bank, banking, Belgian, biomarker, biopharma, BRCA, California, carcinoma, Carvykti, Catalent, checkpoint, chemo, chromatin, ciltacabtagene, CLS, CMO, coated, complementary, composed, concentrated, Concord, conducive, correction, cytotoxic, deal, default, degrade, Delaware, Deoxyribonuclease, depth, diagnostic, DNase, ductal, durability, EirGen, elevated, enzyme, Epidemiology, epigenetically, excessive, expelled, exploratory, extracellular, fashion, faster, FDIC, fifteen, Fluorouracil, FOLFIRINOX, gemcitabine, generalizable, highest, highlighting, hostile, hour, hydrodynamic, immunosuppression, immunosuppressive, implicated, infiltrate, infiltration, inhibitor, interventional, Janssen, KEYTRUDA, knowledge, Kornberg, lending, leucovorin, lieu, lingering, LV, Lynparza, Macarulla, matrix, median, Merck, metastasized, metastatic, microbial, microenvironment, modulator, multicenter, mutated, neutrophil, nonpayment, occlude, Onivyde, optimize, Overview, pancreatic, PDAC, penetration, PHSA, polypeptide, prioritize, prioritized, radio, receivership, refile, regularly, remarkable, rhDNase, Roger, SARL, SEER, signaling, Silicon, Silvergate, SOW, specialty, subscribe, SVB, swept, thereunder, tiered, tighter, troubled, TSRI, uncured, undrawn, uninsured, Valley, Volition, wage, weblike, widespread

Removed: abandoned, adapt, aggressive, aim, Bioorganic, borrowing, carryforward, casting, chair, concept, contemplating, coupled, CRS, curative, cytokine, death, decided, die, diffuse, EMA, enhanced, failing, fatal, fault, feet, focusing, follicular, fueled, generating, genetically, graft, guideline, GvHD, hope, HSCT, IBCH, implicit, incremental, incurable, informative, initiation, judgmental, lowered, lymphocytic, lymphoplasmacytic, mantle, marginal, modality, monetization, myriad, neurologic, NHL, occupy, offered, opportunistically, participant, pharmacokinetic, pro, promise, pursued, quickly, rata, recurrence, refractory, refundable, relapse, representation, rest, shareholder, Speen, square, steering, sublease, syndrome, tech, transplant, treated, vaccine, view, zone

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

XBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Xenetic Biosciences, Inc. (the “Company”) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned officers of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 22, 2023

/s/ Jeffrey F. Eisenberg

/s/James Parslow

Jeffrey F. Eisenberg

James Parslow

Chief Executive Officer

(Principal Executive Officer)

Chief Financial Officer

(Principal Financial Officer)